G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? So please join us as we prepare with a few cups of stimulation — our choice today is apple cider donut — and remember, no prescription is required. Meanwhile, here are some items of interest to help you along. Hope your day is smashing and, as always, do keep in touch …

Novartis (NVS) offered $3.9 billion in cash for Advanced Accelerator Applications (AAAP), providing a platform in radiopharmaceuticals that treat tumors. Last August, European regulators approved a ground-breaking, gene-modifying leukemia treatment developed by AAA, which hopes to win approval from the U.S. Food and Drug Administration in early 2018. Two years ago, Novartis purchased the GlaxoSmithKline (GSK) commercial cancer portfolio.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.